Per the filing, 2025 revenue was about KRW 19 million, with an operating loss of KRW 1,269 million and a net loss of KRW 1,432 million. The latest revenue figure the company disclosed is KRW 19.2 million.
In 2024 there was no revenue, the operating loss was KRW 3,130.57 million and the net loss was KRW 3,806.52 million. The loss narrowed in 2025, but the revenue base remains minimal.
At the end of 2025, total equity was negative KRW 4,067 million, and total liabilities of KRW 6,921 million exceeded total assets of KRW 2,854 million. On the commercial side, the company signed a domestic sales contract with Humanwellness on April 3, 2026, with a delivery period from April 3 to October 10, 2026.
No filing on 2026 quarterly results was confirmed, so none are described here. The share price has ranged between a 52-week low of KRW 4,200 and a high of KRW 6,950, and on October 8, 2026 the open, high, low and close were all KRW 4,635.
At the time of writing, the price is KRW 4,635, trading value is zero and market capitalization is KRW 18.7 billion.